GenFleet Doses First Patients in China, Australia in GFH276 Combination Trial for Pancreatic CancerPUBT·Nov 16, 2026 at 12:01 AM02595+1.18%
Weekly Recap | GENFLEET-B -3.73%, most brokers rate it buyWeekly Review·Nov 14, 2026 at 05:25 AM02595+1.18%
Genfleet Therapeutics discloses share buyback in HKEX next-day returnPUBT·Nov 13, 2026 at 09:14 AM02595+1.18%
Genfleet Therapeutics files HKEX next-day disclosure return announcing share buybackPUBT·Nov 8, 2026 at 10:07 AM02595+1.18%
Weekly Recap | GENFLEET-B +5.01%, GFH276 combos gain clinical clearanceWeekly Review·Nov 7, 2026 at 05:56 AM02595+1.18%
GenFleet surges 12% as GFH276 combo therapy gets trial nodMarket Movers·Nov 4, 2026 at 06:12 AM02595+1.18%
GenFleet Advances GFH276 Combination Studies in RAS-Mutant CancersTip Ranks·Nov 3, 2026 at 11:42 PM02595+1.18%